News | August 13, 2021
JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Anti-malaria API facility will be operational in 15-18 months
It plays a pivotal role in monitoring pharmaceutical pricing
A treatment to prevent extreme symptoms and cut hospitalisation
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
If approved it will bring a second source of MMR vaccine to the US market
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Subscribe To Our Newsletter & Stay Updated
